BlueCrest Capital Management’s bluebird bio BLUE Stock Holding History

BlueCrest Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-973	Closed	-$1.98M	–	478
2019 Q1	$1.98M	Buy	+973	New	+$1.71M	0.08%	177
2018 Q4	–	Sell	-1,962	Closed	-$3.71M	–	896
2018 Q3	$3.71M	Sell	1,962 -1,151	-37%	-$2.38M	0.1%	139
2018 Q2	$6.33M	Buy	3,113 +2,113	+211%	+$4.82M	0.16%	135
2018 Q1	$2.21M	Buy	+1,000	New	+$2.54M	0.07%	285
2017 Q3	–	Sell	-352	Closed	-$479K	–	855
2017 Q2	$479K	Buy	+352	New	+$425K	0.02%	599
2015 Q3	–	Sell	-664	Closed	-$1.45M	–	871
2015 Q2	$1.45M	Buy	+664	New	+$1.35M	0.04%	423

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's BLUE Position: Q2 2019 in Review

BlueCrest Capital Management sold out of bluebird bio (BLUE) in Q2 2019, closing a stake of 973 shares — an estimated $1.98M sold.

BlueCrest Capital Management first reported a position in BLUE in Q2 2015 and held it in 6 quarters. The position peaked at $6.33M in Q2 2018. 273 funds tracked by Wall St. Rank hold BLUE as of Q2 2019.

BlueCrest Capital Management reported no remaining bluebird bio position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 973 bluebird bio shares in Q2 2019, an estimated $1.98M.
BlueCrest Capital Management first reported a position in bluebird bio in Q2 2015 and held it in 6 quarters.
BlueCrest Capital Management's bluebird bio position peaked at $6.33M in Q2 2018.
273 funds tracked by Wall St. Rank held bluebird bio as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.